NxStage Medical 10-Q 6 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 29, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	NXTM
Entity Registrant Name	NxStage Medical, Inc.
Entity Central Index Key	1333170
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		63,238,267

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$51,012	$52,884
Accounts receivable, net	23,989	24,099
Inventory	45,277	45,401
Prepaid expenses and other current assets	6,382	6,767
Total current assets	126,660	129,151
Property and equipment, net	64,209	66,574
Field equipment, net	21,661	21,118
Deferred cost of revenues	33,798	34,039
Intangible assets, net	13,629	14,370
Goodwill	41,817	41,817
Other assets	2,826	2,657
Total assets	304,600	309,726
Current liabilities:
Accounts payable	16,959	13,845
Accrued expenses	21,139	24,653
Current portion of long-term debt	84	93
Other current liabilities	5,388	6,165
Total current liabilities	43,570	44,756
Deferred revenues	51,697	52,943
Long-term debt	746	848
Other long-term liabilities	18,379	19,624
Total liabilities	114,392	118,171
Commitments and contingencies (Note 9)
Stockholders' equity:
Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2015 and December 31, 2014
Common stock: par value $0.001, 100,000,000 shares authorized; 64,007,122 and 63,429,005 shares issued as of March 31, 2015 and December 31, 2014, respectively	64	63
Additional paid-in capital	598,753	593,073
Accumulated deficit	-393,146	-387,488
Accumulated other comprehensive loss	-2,968	-2,192
Treasury stock, at cost: 794,588 and 772,273 shares as of March 31, 2015 and December 31, 2014, respectively	-13,378	-12,989
Total NxStage Medical, Inc. stockholders' equity	189,325	190,467
Noncontrolling interest	883	1,088
Total stockholders' equity	190,208	191,555
Total liabilities and stockholders' equity	$304,600	$309,726

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Undesignated preferred stock, par value	$0.00	$0.00
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	64,007,122	63,429,005
Treasury stock, shares	794,588	772,273

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Revenues	$79,482	$72,221
Cost of revenues	49,356	43,287
Gross profit	30,126	28,934
Operating expenses:
Selling and marketing	14,548	13,218
Research and development	5,874	5,134
Distribution	6,371	6,550
General and administrative	8,912	8,821
Total operating expenses	35,705	33,723
Loss from operations	-5,579	-4,789
Other expense:
Interest expense	-241	-198
Other income, net	264	23
Total other expenses	23	-175
Net loss before income taxes	-5,556	-4,964
Provision for income taxes	307	346
Net loss	-5,863	-5,310
Less: Net loss attributable to noncontrolling interests	-205	-35
Net loss attributable to stockholders of NxStage Medical, Inc.	-5,658	-5,275
Net loss per share, basic and diluted	($0.09)	($0.09)
Weighted-average shares outstanding, basic and diluted	62,836	61,252
Other comprehensive (loss) income	-776	182
Total comprehensive loss	-6,639	-5,128
Less: Comprehensive loss attributable to noncontrolling interests	-205	-35
Total comprehensive loss attributable to stockholders of NxStage Medical, Inc.	($6,434)	($5,093)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($5,863)	($5,310)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,680	6,591
Stock-based compensation	3,727	2,641
Other	508	80
Changes in operating assets and liabilities:
Accounts receivable	2	-5,118
Inventory	-5,688	-8,224
Prepaid expenses and other assets	81	-393
Accounts payable	3,650	7,702
Accrued expenses and other liabilities	-3,158	-339
Deferred revenues	-523	-1,010
Net cash provided by (used in) operating activities	416	-3,380
Cash flows from investing activities:
Purchases of property and equipment	-2,025	-4,915
Net cash used in investing activities	-2,025	-4,915
Cash flows from financing activities:
Proceeds from stock award exercises and other share issuances, net	967	1,460
Repayments on loans and lines of credit	-10	-12
Repayments on capital leases	-394	-387
Net cash provided by financing activities	563	1,061
Foreign exchange effect on cash and cash equivalents	-826	-71
Decrease in cash and cash equivalents	-1,872	-7,305
Cash and cash equivalents, beginning of period	52,884	84,134
Cash and cash equivalents, end of period	$51,012	$76,829

Nature_of_Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Operations	1. Nature of Operations
	We are a medical device company that develops, manufactures and markets innovative products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Our primary product, the System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent dialysis and nocturnal dialysis, which clinical literature suggests provides patients better clinical outcomes and improved quality of life. The System One is cleared or approved for commercial sale in the U.S., Canada and certain other markets, and is CE marked in the EU, for the treatment of acute and chronic kidney failure and fluid overload. The System One is cleared specifically by the U.S. Food and Drug Administration (FDA) for home hemodialysis and home nocturnal hemodialysis, as well as therapeutic plasma exchange in a clinical environment. The System One is also CE marked in the EU for home nocturnal hemodialysis. In February 2013, we received CE mark approval and in April 2013 we received clearance from the FDA for the new high flow capabilities with the NxStage System One. We began selling the System One with this feature to both U.S. customers and international distributors in 2014. We also sell, through our Medisystems subsidiary, blood tubing sets and needles primarily to dialysis centers for the treatment of end-stage renal disease (ESRD). These products are cleared or approved for commercial sale in the U.S., Canada and certain other markets and are CE marked in the EU. We believe our largest market opportunity is for the System One used in the home dialysis market for the treatment of ESRD. We operate a small number of NxStage Kidney Care dialysis centers focused on supporting home therapy and providing flexible in-center options with NxStage technology as part of our market development activities to increase home therapy access. We continue to make significant investments in marketing, research and development, and these dialysis centers, all of which are intended to help us to further penetrate and expand the market for our products.
	Basis of Presentation
	The accompanying condensed consolidated financial statements as of March 31, 2015 and for the three months then ended, and related notes, are unaudited but, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments, that are necessary for fair statement of the interim periods presented. Our unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under these rules, we have condensed or omitted certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles (GAAP). Our accounting policies are described in the notes to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014 (2014 Form 10-K) and updated, as necessary, in this Quarterly Report on Form 10-Q. Operating results for any interim period are not necessarily indicative of results for the entire year or future periods. The December 31, 2014 condensed consolidated balance sheet contained herein was derived from audited financial statements, but does not include all disclosures that would be required for audited financial statements under GAAP. For further information, refer to the consolidated financial statements and footnotes thereto included in our 2014 Form 10-K.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Principles of Consolidation and Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of NxStage Medical, Inc. and our wholly-owned and majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	The preparation of our condensed consolidated financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable is primarily limited to certain customers to whom we make substantial sales. One customer represented 18% of accounts receivable at March 31, 2015 and two customers represented 18% and 16% of accounts receivable at December 31, 2014.
	Warranty Costs
	We accrue estimated costs that we may incur under our product warranty programs at the time the product revenue is recognized based on contractual rights and historical experience. Warranty expense is included in cost of revenues in the condensed consolidated statements of comprehensive loss. The following is a rollforward of our warranty accrual (in thousands):
	Balance at December 31, 2014	$	287
	Provision		175
	Usage		(122	)
	Balance at March 31, 2015	$	340
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. We are currently assessing the potential impact the adoption of this standard will have on our financial statements.
	In April 2015, the FASB issued ASU 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. ASU 2015-03 is not expected to have a material impact on our financial statements.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	3. Inventory
	Inventory includes material, labor and overhead, and is stated at lower of cost (first-in, first-out) or market. The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Purchased components	$	19,270	$	19,238
	Work in process		11,104		9,981
	Finished goods		14,903		16,182
	Total	$	45,277	$	45,401

Property_and_Equipment_and_Fie

Property and Equipment and Field Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment and Field Equipment	4. Property and Equipment and Field Equipment
	Accumulated depreciation on property and equipment was $29.5 million and $27.9 million at March 31, 2015 and December 31, 2014, respectively. Accumulated depreciation on field equipment was $41.1 million and $40.0 million at March 31, 2015 and December 31, 2014, respectively.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets
	Accumulated amortization of intangible assets was $21.0 million and $20.3 million at March 31, 2015 and December 31, 2014, respectively.

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	6. Net Loss per Share
	Basic net loss per share is computed by dividing loss attributable to NxStage Medical, Inc. common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period. The computation of diluted loss per share is similar to basic loss per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potentially dilutive common shares had been issued.
	The following potential common stock equivalents, as calculated using the treasury stock method, were not included in the computation of diluted net loss per share as their effect would have been anti-dilutive due to the net loss incurred (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Options to purchase common stock		904		943
	Unvested restricted stock		428		237
	Total		1,332		1,180

Accrued_Expenses_Other_Current

Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities	7. Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities
	The components of accrued expenses are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Payroll, compensation and related benefits	$	9,215	$	12,346
	Distribution expenses		3,124		3,069
	General and administrative expenses		2,801		3,075
	Audit, legal and consulting fees		1,545		1,394
	Other		4,454		4,769
	Total	$	21,139	$	24,653
	The components of other current liabilities are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Capital lease obligations	$	2,082	$	2,246
	Deferred revenue, current portion		2,036		2,195
	Other		1,270		1,724
	Total	$	5,388	$	6,165
	The components of other long-term liabilities are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Capital lease obligations	$	11,084	$	11,876
	Lease incentive obligations		4,382		4,569
	Benefit plan obligations		1,637		1,745
	Other		1,276		1,434
	Total	$	18,379	$	19,624

Segment_Disclosures

Segment Disclosures	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Disclosures	8. Segment Disclosures
	We have three reportable business segments: System One, In-Center, and Services. The operating results of NxStage Kidney Care are included in our Services segment. We distribute our products in three markets: home, critical care and in-center.
	Our System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. The home market is devoted to the treatment of ESRD patients in the home or a home-like setting, while the critical care market is devoted to the treatment of hospital-based patients with acute kidney failure or fluid overload. Some of our largest customers in the home market provide outsourced renal dialysis services to some of our customers in the critical care market. Sales of product to both markets are made primarily through dedicated sales forces and distributed directly to the customer, or the patient, with certain products sold through distributors. The results of our international business are included in the System One segment.
	Our In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors.
	Our Services segment includes revenues from dialysis services provided to patients at our NxStage Kidney Care dialysis centers.
	The remainder of our operations and financial information, included within the Other category, relates to the manufacturing of dialyzers for sale to Asahi Kasei Kuraray Medical Co., Ltd. (Asahi) and research and development and general and administrative expenses that are excluded from the segment operating performance measures.
	The accounting policies of our reportable segments are described in Note 2 to the consolidated financial statements included in our 2014 Form 10-K and updated, as necessary, in Note 2 to the condensed consolidated financial statements included in this Quarterly Report. Our chief operating decision maker allocates resources to our business segments and assesses segment performance based on segment profit (loss), which consists of revenues less cost of revenues, selling and marketing and distribution expenses.
	The following summarizes the operating performance of our reportable segments (in thousands):
		System One			In-Center			Other			Services			Intersegment			Total
														Revenue
														Elimination
	Three Months Ended March 31, 2015
	Revenues from external customers	$	59,098		$	17,867		$	1,847		$	670		$	—		$	79,482
	Intersegment revenues		482			—			—			—			(482	)		—
	Revenues		59,580			17,867			1,847			670			(482	)		79,482
	Segment profit (loss)		12,974			2,177			(14,948	)		(5,782	)		—			(5,579	)
	Depreciation and amortization		5,290			473			1,211			706			—			7,680
	Three Months Ended March 31, 2014
	Revenues from external customers	$	51,135		$	18,916		$	2,054		$	116		$	—		$	72,221
	Intersegment revenues		52			—			—			—			(52	)		—
	Revenues		51,187			18,916		$	2,054			116			(52	)		72,221
	Segment profit (loss)		9,225			2,954			(14,013	)		(2,955	)		—			(4,789	)
	Depreciation and amortization		4,977			276			1,184			154			—			6,591
	Substantially all of our revenues have been derived from the sale of the System One and related products, which cannot be used with any other dialysis system, and from blood tubing sets and needles to customers located in the U.S.
	The following table summarizes the number of customers who individually make up greater than ten percent of total revenues:
		Three Months Ended March 31,
		2015			2014
	DaVita		21	%		22	%
	Fresenius		17	%		15	%
	Gambro		10	%		10	%
	Sales to DaVita and Fresenius are in the System One segment. Sales to Gambro are in the In-Center segment. All of Gambro’s sales of our products are to DaVita.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies
	Significant commitments and contingencies at March 31, 2015 are consistent with those discussed in Note 10 to the consolidated financial statements in our 2014 Form 10-K.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes
	The provision for income taxes of $0.3 million and $0.3 million for the three months ended March 31, 2015 and 2014, respectively, relates to the profitable operations of certain foreign subsidiaries.
	As of March 31, 2015, we had a liability for unrecognized tax benefits included in the balance sheet of approximately $0.3 million, including a nominal accrual for interest and penalties of less than $0.1 million. There have been no significant changes to these amounts during the three months ended March 31, 2015.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation
	Stock-based Compensation Expense
	The following table presents stock-based compensation expense included in our condensed consolidated statements of comprehensive loss (in thousands):
		Three Months Ended March 31,
		2015		2014
	Cost of revenues	$	265	$	198
	Selling and marketing		1,379		855
	Research and development		505		325
	General and administrative		1,578		1,263
	Total	$	3,727	$	2,641
	Stock Options and Restricted Stock Units
	The Company granted options to purchase 914,547 and 769,589 shares of common stock during the three months ended March 31, 2015 and 2014, respectively. The weighted-average fair value of options granted during the three months ended March 31, 2015 and 2014 was $6.10 and $5.98 per option, respectively.
	The Company awarded 122,826 and 168,227 restricted stock units during the three months ended March 31, 2015 and 2014, respectively, which vest based on continued employment over a period of three to four years. The weighted-average fair value of these restricted stock units awarded during the three months ended March 31, 2015 and 2014 was $16.88 and $14.07 per unit, respectively. Furthermore, the Compensation Committee of our Board of Directors approved the grant of up to 316,389 restricted stock units subject to the achievement of certain Company financial performance metrics for the year ending December 31, 2015. The restricted stock units, if earned, vest over a requisite service period of three years and have a fair value of $16.66 per unit.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	12. Stockholders’ Equity
	We received 22,315 and 3,226 shares of common stock that were surrendered in payment for the exercise of stock options during the three months ended March 31, 2015 and 2014, respectively.

Noncontrolling_Interest

Noncontrolling Interest	3 Months Ended
	Mar. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest	13. Noncontrolling Interest
	The following table sets forth the changes in non-controlling interest for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance at beginning of period	$	1,088		$	525
	Net loss attributable to non-controlling interest in consolidated subsidiary		(205	)		(35	)
	Balance at end of period	$	883		$	490

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging	14. Derivative Instruments and Hedging
	We operate a manufacturing and service facility in Mexico and we purchase materials and pay our employees at that facility in pesos, and as such, we are potentially exposed to adverse as well as beneficial movements in foreign currency exchange rates. We enter into foreign exchange forward contracts to minimize the impact of foreign currency exchange rate fluctuations on these peso denominated expenses. These contracts have a duration of up to twelve months and are designated as cash flow hedges. The counterparties to these foreign exchange forward contracts are creditworthy financial institutions; therefore, we do not consider the risk of counterparty nonperformance to be material. As of March 31, 2015 and December 31, 2014, the notional amount of our outstanding contracts that are designated as cash flow hedges was $14.8 million and $12.5 million, respectively. The fair value of these contracts is recorded on the balance sheet within prepaid expenses and other current assets or accrued expenses depending on the gain (loss) position. The fair value of these contracts was a liability of $1.1 million and $1.3 million at March 31, 2015 and December 31, 2014, respectively.
	Gains or losses related to hedge ineffectiveness recognized in earnings were not material during the three months ended March 31, 2015 or 2014. Given the short-term nature of our contracts, any gains or losses recorded within accumulated other comprehensive income (loss) will be recognized in earnings within the next twelve months.
	The following table presents the effect of these contracts designated as cash flow hedges on our condensed consolidated financial statements (in thousands):
		Gain (Loss) Recognized			Gain (Loss) Reclassified			Classification within the
		in OCI			from OCI into Income			Condensed
		(Effective Portion)			(Effective Portion)			Consolidated Statement
								of Comprehensive Loss
	Three Months Ended March 31, 2015
	Foreign exchange forward contracts	$	(345	)	$	(478	)	Cost of revenues
	Three Months Ended March 31, 2014
	Foreign exchange forward contracts	$	33		$	(102	)	Cost of revenues

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss) Income	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income	15. Accumulated Other Comprehensive (Loss) Income
	The following additional information is provided with respect to the accumulated other comprehensive (loss) income as presented on the condensed consolidated balance sheets (in thousands):
			Unrealized gain (loss)			Other (2)			Total
			on derivative
			instruments
	Balance, net of tax, at beginning of period		$	(1,088	)	$	(1,104	)	$	(2,192	)
	Other comprehensive loss before reclassifications			(345	)		(909	)		(1,254	)
	Loss reclassified to earnings (1)			478			—			478
	Total other comprehensive income			133			(909	)		(776	)
	Balance, net of tax, at end of period		$	(955	)	$	(2,013	)	$	(2,968	)
	-1	Reclassifications of gains (losses) on derivative instruments are included in cost of revenues on the condensed consolidated statement of comprehensive loss. See Note 14 for further information.
	-2	Other includes cumulative translation adjustments and, to a lesser extent, pension benefits.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	16. Fair Value Measurements
	We have certain financial assets and liabilities measured at fair value on a recurring and non-recurring basis recorded in our condensed consolidated balance sheets. The fair value measurements used are based on quoted prices, when available, or through the use of alternative approaches. The inputs used to determine fair value have been classified as Level 1, 2 or 3. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves for similar instruments and model-derived valuations whose inputs are observable. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.
	We measure the fair value of our foreign exchange forward contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.
	We did not have any transfers between Level 1 and Level 2 and Level 3 during the three months ended March 31, 2015.
	The following table presents assets and liabilities measured at fair value on a recurring basis and their level within the value hierarchy (in thousands):
	March 31, 2015		Quoted Prices in		Significant Other		Significant		Total Fair
			Active Markets		Observable		Unobservable		Value
			for Identical		Inputs		Inputs
			Assets		(Level 2)		(Level 3)
			(Level 1)
	Assets
	Money market funds (1)		$	34,778	$	—	$	—	$	34,778
	Foreign exchange forward contracts (2)			—		21		—		21
	Liabilities
	Foreign exchange forward contracts (2)		$	—	$	1,149	$	—	$	1,149
	December 31, 2014		Quoted Prices in		Significant Other		Significant		Total Fair
			Active Markets		Observable		Unobservable		Value
			for Identical		Inputs		Inputs
			Assets		(Level 2)		(Level 3)
			(Level 1)
	Assets
	Money market funds (1)		$	39,779	$	—	$	—	$	39,779
	Liabilities
	Foreign exchange forward contracts (2)		$	—	$	1,265	$	—	$	1,265
	-1	Money market funds are included within cash and cash equivalents.
	-2	Foreign exchange forward contracts are included within prepaid expenses and other current assets or accrued expenses depending on the gain (loss) position.
	The carrying amount of our long-term debt approximates fair value at March 31, 2015 and December 31, 2014. The fair value of our long-term debt was estimated using inputs derived principally from market observable data, including current rates offered to us for debt of the same or similar remaining maturities. Within the hierarchy of fair value measurements, these are Level 2 inputs.
	The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, prepaid expenses and other current and non-current assets, accounts payable and accrued expenses approximate fair value due to their short-term nature.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	17. Supplemental Cash Flow Information
	The following additional information is provided with respect to the condensed consolidated statements of cash flows (in thousands):
		Three Months Ended March 31,
		2015		2014
	Noncash Investing and Financing Activities:
	Transfers from inventory to field equipment	$	5,073	$	4,987
	Transfers from field equipment to deferred cost of revenues		3,160		2,260
	Payment of corporate bonus in common stock		1,103		—
	Market value of shares received in payment for exercise of stock options		389		47
	Construction-in-process financed by construction liability		324		969
	Property and equipment acquired under capital lease		354		—

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of NxStage Medical, Inc. and our wholly-owned and majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of our condensed consolidated financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable is primarily limited to certain customers to whom we make substantial sales. One customer represented 18% of accounts receivable at March 31, 2015 and two customers represented 18% and 16% of accounts receivable at December 31, 2014.
Warranty Costs	Warranty Costs
	We accrue estimated costs that we may incur under our product warranty programs at the time the product revenue is recognized based on contractual rights and historical experience. Warranty expense is included in cost of revenues in the condensed consolidated statements of comprehensive loss. The following is a rollforward of our warranty accrual (in thousands):
	Balance at December 31, 2014	$	287
	Provision		175
	Usage		(122	)
	Balance at March 31, 2015	$	340
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. On April 1, 2015 the FASB voted in favor of proposing a one year delay of the effective date and to permit companies to voluntarily adopt the new standard as of the original effective date. We are currently assessing the potential impact the adoption of this standard will have on our financial statements.
	In April 2015, the FASB issued ASU 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. ASU 2015-03 is not expected to have a material impact on our financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Rollforward of Warranty Accrual	The following is a rollforward of our warranty accrual (in thousands):
	Balance at December 31, 2014	$	287
	Provision		175
	Usage		(122	)
	Balance at March 31, 2015	$	340

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Purchased components	$	19,270	$	19,238
	Work in process		11,104		9,981
	Finished goods		14,903		16,182
	Total	$	45,277	$	45,401

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Net Loss Per Share	The following potential common stock equivalents, as calculated using the treasury stock method, were not included in the computation of diluted net loss per share as their effect would have been anti-dilutive due to the net loss incurred (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Options to purchase common stock		904		943
	Unvested restricted stock		428		237
	Total		1,332		1,180

Accrued_Expenses_Other_Current1

Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	The components of accrued expenses are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Payroll, compensation and related benefits	$	9,215	$	12,346
	Distribution expenses		3,124		3,069
	General and administrative expenses		2,801		3,075
	Audit, legal and consulting fees		1,545		1,394
	Other		4,454		4,769
	Total	$	21,139	$	24,653
Components of Other Current liabilities	The components of other current liabilities are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Capital lease obligations	$	2,082	$	2,246
	Deferred revenue, current portion		2,036		2,195
	Other		1,270		1,724
	Total	$	5,388	$	6,165
Components of Other Long-term Liabilities	The components of other long-term liabilities are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Capital lease obligations	$	11,084	$	11,876
	Lease incentive obligations		4,382		4,569
	Benefit plan obligations		1,637		1,745
	Other		1,276		1,434
	Total	$	18,379	$	19,624

Segment_Disclosures_Tables

Segment Disclosures (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Summary of Operating Performance of Reportable Segments	The following summarizes the operating performance of our reportable segments (in thousands):
		System One			In-Center			Other			Services			Intersegment			Total
														Revenue
														Elimination
	Three Months Ended March 31, 2015
	Revenues from external customers	$	59,098		$	17,867		$	1,847		$	670		$	—		$	79,482
	Intersegment revenues		482			—			—			—			(482	)		—
	Revenues		59,580			17,867			1,847			670			(482	)		79,482
	Segment profit (loss)		12,974			2,177			(14,948	)		(5,782	)		—			(5,579	)
	Depreciation and amortization		5,290			473			1,211			706			—			7,680
	Three Months Ended March 31, 2014
	Revenues from external customers	$	51,135		$	18,916		$	2,054		$	116		$	—		$	72,221
	Intersegment revenues		52			—			—			—			(52	)		—
	Revenues		51,187			18,916		$	2,054			116			(52	)		72,221
	Segment profit (loss)		9,225			2,954			(14,013	)		(2,955	)		—			(4,789	)
	Depreciation and amortization		4,977			276			1,184			154			—			6,591
Summary of Number of Customers Who Individually Make Up Greater than 10% of Total Revenues	The following table summarizes the number of customers who individually make up greater than ten percent of total revenues:
		Three Months Ended March 31,
		2015			2014
	DaVita		21	%		22	%
	Fresenius		17	%		15	%
	Gambro		10	%		10	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense in Consolidated Statements of Comprehensive Loss	The following table presents stock-based compensation expense included in our condensed consolidated statements of comprehensive loss (in thousands):
		Three Months Ended March 31,
		2015		2014
	Cost of revenues	$	265	$	198
	Selling and marketing		1,379		855
	Research and development		505		325
	General and administrative		1,578		1,263
	Total	$	3,727	$	2,641

Noncontrolling_Interest_Tables

Noncontrolling Interest (Tables)	3 Months Ended
	Mar. 31, 2015
Noncontrolling Interest [Abstract]
Schedule of Changes in Non-controlling Interest	The following table sets forth the changes in non-controlling interest for the three months ended March 31, 2015 and 2014 (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance at beginning of period	$	1,088		$	525
	Net loss attributable to non-controlling interest in consolidated subsidiary		(205	)		(35	)
	Balance at end of period	$	883		$	490

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Effect of Contracts Designated as Cash Flow Hedges on Consolidated Financial Statements	The following table presents the effect of these contracts designated as cash flow hedges on our condensed consolidated financial statements (in thousands):
		Gain (Loss) Recognized			Gain (Loss) Reclassified			Classification within the
		in OCI			from OCI into Income			Condensed
		(Effective Portion)			(Effective Portion)			Consolidated Statement
								of Comprehensive Loss
	Three Months Ended March 31, 2015
	Foreign exchange forward contracts	$	(345	)	$	(478	)	Cost of revenues
	Three Months Ended March 31, 2014
	Foreign exchange forward contracts	$	33		$	(102	)	Cost of revenues

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Additional Information on Accumulated Other Comprehensive (Loss) Income	The following additional information is provided with respect to the accumulated other comprehensive (loss) income as presented on the condensed consolidated balance sheets (in thousands):
			Unrealized gain (loss)			Other (2)			Total
			on derivative
			instruments
	Balance, net of tax, at beginning of period		$	(1,088	)	$	(1,104	)	$	(2,192	)
	Other comprehensive loss before reclassifications			(345	)		(909	)		(1,254	)
	Loss reclassified to earnings (1)			478			—			478
	Total other comprehensive income			133			(909	)		(776	)
	Balance, net of tax, at end of period		$	(955	)	$	(2,013	)	$	(2,968	)
	-1	Reclassifications of gains (losses) on derivative instruments are included in cost of revenues on the condensed consolidated statement of comprehensive loss. See Note 14 for further information.
	-2	Other includes cumulative translation adjustments and, to a lesser extent, pension benefits.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents assets and liabilities measured at fair value on a recurring basis and their level within the value hierarchy (in thousands):
	March 31, 2015		Quoted Prices in		Significant Other		Significant		Total Fair
			Active Markets		Observable		Unobservable		Value
			for Identical		Inputs		Inputs
			Assets		(Level 2)		(Level 3)
			(Level 1)
	Assets
	Money market funds (1)		$	34,778	$	—	$	—	$	34,778
	Foreign exchange forward contracts (2)			—		21		—		21
	Liabilities
	Foreign exchange forward contracts (2)		$	—	$	1,149	$	—	$	1,149
	December 31, 2014		Quoted Prices in		Significant Other		Significant		Total Fair
			Active Markets		Observable		Unobservable		Value
			for Identical		Inputs		Inputs
			Assets		(Level 2)		(Level 3)
			(Level 1)
	Assets
	Money market funds (1)		$	39,779	$	—	$	—	$	39,779
	Liabilities
	Foreign exchange forward contracts (2)		$	—	$	1,265	$	—	$	1,265
	-1	Money market funds are included within cash and cash equivalents.
	-2	Foreign exchange forward contracts are included within prepaid expenses and other current assets or accrued expenses depending on the gain (loss) position.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Summary of Supplemental Cash Flow Information	The following additional information is provided with respect to the condensed consolidated statements of cash flows (in thousands):
		Three Months Ended March 31,
		2015		2014
	Noncash Investing and Financing Activities:
	Transfers from inventory to field equipment	$	5,073	$	4,987
	Transfers from field equipment to deferred cost of revenues		3,160		2,260
	Payment of corporate bonus in common stock		1,103		—
	Market value of shares received in payment for exercise of stock options		389		47
	Construction-in-process financed by construction liability		324		969
	Property and equipment acquired under capital lease		354		—

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (Customer Concentration Risk [Member], Accounts Receivable [Member])	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Major Customer One [Member]
Accounting Policies [Line Items]
Percentage of accounts receivable	18.00%	18.00%
Major Customer Two [Member]
Accounting Policies [Line Items]
Percentage of accounts receivable		16.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Rollforward of Warranty Accrual (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Accounting Policies [Abstract]
Balance at Beginning of Year	$287
Provision	175
Usage	-122
Balance at End of Year	$340

Inventory_Components_of_Invent

Inventory - Components of Inventory (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Purchased components	$19,270	$19,238
Work in process	11,104	9,981
Finished goods	14,903	16,182
Total	$45,277	$45,401

Property_and_Equipment_and_Fie1

Property and Equipment and Field Equipment - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Property And Equipment Excluding Field Equipment [Member]
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$29.50	$27.90
Field Equipment [Member]
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$41.10	$40

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated amortization of intangible assets	$21	$20.30

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Anti-dilutive Net Loss Per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from computation of earnings per share	1,332	1,180
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from computation of earnings per share	904	943
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from computation of earnings per share	428	237

Accrued_Expenses_Other_Current2

Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities - Components of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Payroll, compensation and related benefits	$9,215	$12,346
Distribution expenses	3,124	3,069
General and administrative expenses	2,801	3,075
Audit, legal and consulting fees	1,545	1,394
Other	4,454	4,769
Total	$21,139	$24,653

Accrued_Expenses_Other_Current3

Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities - Components of Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Capital lease obligations	$2,082	$2,246
Deferred revenue, current portion	2,036	2,195
Other	1,270	1,724
Total	$5,388	$6,165

Accrued_Expenses_Other_Current4

Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities - Components of Other Long-term Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Liabilities, Noncurrent [Abstract]
Capital lease obligations	$11,084	$11,876
Lease incentive obligations	4,382	4,569
Benefit plan obligations	1,637	1,745
Other	1,276	1,434
Total	$18,379	$19,624

Segment_Disclosures_Additional

Segment Disclosures - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Markets
	Segment
Segment Reporting [Abstract]
Number of reporting segments	3
Number of markets product distributed	3

Segment_Disclosures_Summary_of

Segment Disclosures - Summary of Operating Performance of Reportable Segments (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$79,482	$72,221
Segment profit (loss)	-5,579	-4,789
Depreciation and amortization	7,680	6,591
System One [Member]
Segment Reporting Information [Line Items]
Revenues	59,580	51,187
Segment profit (loss)	12,974	9,225
Depreciation and amortization	5,290	4,977
In-Center [Member]
Segment Reporting Information [Line Items]
Revenues	17,867	18,916
Segment profit (loss)	2,177	2,954
Depreciation and amortization	473	276
Services [Member]
Segment Reporting Information [Line Items]
Revenues	670	116
Segment profit (loss)	-5,782	-2,955
Depreciation and amortization	706	154
Other Member]
Segment Reporting Information [Line Items]
Revenues	1,847	2,054
Segment profit (loss)	-14,948	-14,013
Depreciation and amortization	1,211	1,184
Intersegment Revenue Elimination [Member]
Segment Reporting Information [Line Items]
Revenues	-482	-52
Intersegment Revenue Elimination [Member] | System One [Member]
Segment Reporting Information [Line Items]
Revenues	-482	-52
Operating Segments [Member] | System One [Member]
Segment Reporting Information [Line Items]
Revenues	59,098	51,135
Operating Segments [Member] | In-Center [Member]
Segment Reporting Information [Line Items]
Revenues	17,867	18,916
Operating Segments [Member] | Services [Member]
Segment Reporting Information [Line Items]
Revenues	$670	$116

Segment_Disclosures_Summary_of1

Segment Disclosures - Summary of Number of Customers Who Individually Make Up Greater than 10% of Total Revenues (Detail) (Sales Revenue, Net [Member], Customer Concentration Risk [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
DaVita [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues	21.00%	22.00%
Fresenius [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues	17.00%	15.00%
Gambro [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues	10.00%	10.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Schedule of Income Tax [Line Items]
Foreign tax expense	$300,000	$300,000
Liability for unrecognized tax benefits	300,000
Significant changes in unrecognized tax benefits	0
Maximum [Member]
Schedule of Income Tax [Line Items]
Accrued interest and penalties	$100,000

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock-Based Compensation Expense in Consolidated Statements of Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$3,727	$2,641
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	265	198
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	1,379	855
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	505	325
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$1,578	$1,263

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Options to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	914,547	769,589
Weighted-average fair value of options granted	$6.10	$5.98
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	122,826	168,227
Weighted-average fair value of restricted stock granted	$16.88	$14.07
Restricted Stock Units (RSUs) [Member] | Performance Based Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	316,389
Weighted-average fair value of restricted stock granted	$16.66
Restricted stock vests over a requisite service period	3 years
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Shares delivered or surrendered in payment for the exercise of stock options	22,315	3,226

Noncontrolling_Interest_Schedu

Noncontrolling Interest - Schedule of Changes in Non-controlling Interest (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Noncontrolling Interest [Abstract]
Balance at beginning of period	$1,088	$525
Net loss attributable to noncontrolling interest in consolidated subsidiary	-205	-35
Balance at end of period	$883	$490

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Hedging Transactions And Derivative Financial Instruments [Line Items]
Period of cash flow hedges	12 months
Cash Flow Hedges [Member]
Hedging Transactions And Derivative Financial Instruments [Line Items]
Notional amount of outstanding contracts	14.8	$12.50
Fair value of outstanding contracts liability	1.1	$1.30

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging - Effect of Contracts Designated as Cash Flow Hedges on Consolidated Financial Statements (Detail) (Cost of Revenues [Member], Cash Flow Hedges [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cost of Revenues [Member] | Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI (Effective Portion)	($345)	$33
Gain (Loss) Reclassified from OCI into Income (Effective Portion)	($478)	($102)
Classification within the Condensed Consolidated Statement of Comprehensive Loss	Cost of revenues

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income - Summary of Additional Information on Accumulated Other Comprehensive (Loss) Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance net of tax	($2,192)
Other comprehensive loss before reclassifications	-1,254
Loss reclassified to earnings	478
Total other comprehensive income	-776	182
Ending balance net of tax	-2,968
Other [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance net of tax	-1,104
Other comprehensive loss before reclassifications	-909
Total other comprehensive income	-909
Ending balance net of tax	-2,013
Unrealized Gain (Loss) on Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance net of tax	-1,088
Other comprehensive loss before reclassifications	-345
Loss reclassified to earnings	478
Total other comprehensive income	133
Ending balance net of tax	($955)

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value Measurements, Recurring Basis [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Foreign Exchange Forward Contracts [Member]
Assets
Foreign exchange forward contracts	$21
Liabilities
Foreign exchange forward contracts	1,149	1,265
Significant Other Observable Inputs (Level 2) [Member] | Foreign Exchange Forward Contracts [Member]
Assets
Foreign exchange forward contracts	21
Liabilities
Foreign exchange forward contracts	1,149	1,265
Money Market Funds [Member]
Assets
Money market funds	34,778	39,779
Money Market Funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets
Money market funds	$34,778	$39,779

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information - Summary of Supplemental Cash Flow Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Noncash Investing and Financing Activities:
Transfers from inventory to field equipment	$5,073	$4,987
Transfers from field equipment to deferred cost of revenues	3,160	2,260
Payment of corporate bonus in common stock	1,103
Market value of shares received in payment for exercise of stock options	389	47
Construction-in-process financed by construction liability	324	969
Property and equipment acquired under capital lease	$354